Veracyte, INC Form 4 insider transactions

Director Karin Eastham of Veracyte, Inc. acquired 5,272 shares of common stock on June 11, 2026, increasing her beneficial ownership.

Veracyte, Inc. Director Evan Jones acquired 5,272 shares of common stock on June 11, 2026, as detailed in a Form 4 filing.

Veracyte, Inc. Director David Brent Shafer acquired 5,272 shares of common stock on June 11, 2026, as part of a restricted stock unit award.

Director Eliav Barr of Veracyte, Inc. (VCYT) acquired 5,272 shares of common stock on June 11, 2026, increasing his beneficial ownership.

Veracyte, Inc. Director Robert S. Epstein acquired 5,272 shares of common stock on June 11, 2026, as part of an award of restricted stock units.

Veracyte, Inc. Director Jens Holstein acquired 5,272 shares of common stock on June 11, 2026, increasing his beneficial ownership.

Veracyte, Inc. Director Muna Bhanji acquired 5,272 shares of common stock on June 11, 2026, increasing beneficial ownership to 44,582 shares.

Veracyte, Inc. Director Thomas F. Miller acquired 5,272 shares of common stock on June 11, 2026, as part of a restricted stock unit award.

Veracyte's General Counsel Annie McGuire sold 3,176 shares and had 3,292 shares withheld for taxes, totaling over $310,000 in transactions.

Chief Accounting Officer Jonathan Wygant had 1,361 shares withheld to satisfy tax liabilities following the vesting of restricted stock units.

Veracyte Chief Financial Officer Rebecca Chambers sold 3,561 shares and had 3,693 shares withheld for taxes under a pre-arranged trading plan.

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., had 3,730 shares withheld to cover tax liabilities following the vesting of restricted stock units.

Veracyte CEO Marc Stapley exercised options and sold 138,051 shares under a pre-arranged trading plan.

Global Chief Commercial Officer John Leite sold 13,975 shares of Veracyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Veracyte, Inc. VP, Chief Accounting Officer Jonathan Wygant reported transactions involving the sale of 24,000 shares and the acquisition of 24,000 stock options.

Veracyte, Inc. Director Robert S. Epstein sold 10,000 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Veracyte SVP and General Counsel Annie McGuire sold 10,204 shares of common stock via a pre-arranged 10b5-1 trading plan.

Veracyte, Inc. reports a grant of 44,221 shares of common stock to Chief Development and Technology Officer Kevin Richard Haas.

Veracyte's Chief Financial Officer, Rebecca Chambers, sold a total of 18,341 shares of common stock on March 4, 2026, through a pre-arranged 10b5-1 trading plan.

Veracyte CEO Marc Stapley disposed of 45,523 shares of common stock totaling approximately $1.64 million through pre-arranged Rule 10b5-1 trading plans.

Veracyte's Chief Commercial Officer, John Leite, sold 5,260 shares of common stock for approximately $35.19 per share under a pre-arranged 10b5-1 trading plan.

Veracyte's SVP and General Counsel, Annie McGuire, sold 6,658 shares of common stock for approximately $236,770 through a pre-arranged 10b5-1 plan.

Veracyte's SVP, General Counsel, Annie McGuire, reported a disposition of 6,902 common shares for tax withholding related to restricted stock unit vesting.

Veracyte's VP, Chief Accounting Officer, Jonathan Wygant, had 3,006 shares withheld for tax obligations related to restricted stock unit vesting on March 2, 2026.

Veracyte's Chief Financial Officer, Rebecca Chambers, reported a disposition of 7,234 common shares to cover tax obligations related to restricted stock unit vesting.

Veracyte's Chief Commercial Officer, John Leite, reported a disposition of shares to cover tax obligations related to restricted stock unit vesting.

Veracyte's Chief Scientific and Medical Officer, Phillip G. Febbo, reported the sale of 13,425 common shares and the withholding of 6,035 shares for tax obligations.

Veracyte CEO Marc Stapley reported the withholding of 19,455 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Veracyte's Chief Commercial Officer, John Leite, acquired shares through PSU vesting and simultaneously disposed of a portion for tax obligations.

Veracyte CEO Marc Stapley reported the vesting of performance-based restricted stock units and subsequent tax-related share disposition, increasing his direct beneficial ownership.